Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Sanofi
With
Regeneron Pharmaceuticals
Age
20–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Patients with histologically or cytologically proven malignant tumor of the colon or rectum which is metastatic and inoperable.
Patients must have received at least one prior line of treatment with any standard of care, who have failed the treatment, or who have not been eligible for standard of care for safety reasons.
You may not be if
Treatment with chemotherapy, hormone therapy, radiotherapy, surgery, blood products, or any investigational agent within 28 days.
ECOG Performance Status\>1
Anticipated need for a major surgical procedure or radiation therapy during the study.
Uncontrolled malignant ascites.
History of brain metastases, spinal cord compression, or carcinomatous meningitis or new evidence of brain or leptomeningeal disease on screening CT or MRI scan.
Pregnant or breast-feeding women.
Uncontrolled hypertension
Patients who have previously been treated with aflibercept
History of abdominal fistula, GI perforation, or intra-abdominal abscess within the past 28 days.
History of hypersensitivity to any recombinant proteins, irinotecan, fluoropyrimidine or isovorin.
Known dihydropyrimidine dehydrogenase deficiency.
The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
Clareo Health | Study of Intravenous Aflibercept in Combination With FOLFIRI in Japanese Patients With Metastatic Colorectal Cancer
